Background {#Sec1}
==========

Regular exercise is an important strategy to implement to help prevent obesity \[[@CR1]\]. According to the exercise prescription recommended in the American College of Sports Medicine \[[@CR2]\] guidelines, 45--60 min of exercise should be targeted to ensure sufficient energy expenditure in obese people. In particular, the blood levels of several hormones including catecholamines, glucagon, growth hormone, and cortisol are increased during exercise compared with levels in rest periods \[[@CR3]\]. Moreover, several studies reported on acute exercise and lipid utilization, and related hormones in human \[[@CR4]--[@CR6]\]. Therefore, we hypothesize that a combination of exercise and factors that affect the secretion of some of these hormones may be effective for increasing fat catabolism and energy expenditure.

When combined with exercise, dietary amino acid (AA) supplementation is an effective method for accelerating fat mobilization \[[@CR7], [@CR8]\]. It has been reported that previously that pre-ingestion of a single dose of a mixture of specific amino acids (AAs) enhanced lipolysis and hepatic ketogenesis during and after exercise by stimulating glucagon secretion \[[@CR9], [@CR10]\]. However, the effects of single AAs combined with exercise on fat oxidation remains unclear. L-phenylalanine (Phe), a tyrosine precursor, is an essential amino acid, and is a substrate for tyrosine hydroxylase, the enzyme that catalyzes the rate-limiting step in catecholamine synthesis \[[@CR11]\]. It is known that Phe is a dietary requirement for protein synthesis. Nuttall et al. showed that a single oral administration of a large amount of Phe (1 mmol/kg lean body mass) acted as a nutrient-signaling molecule that stimulated an increase in insulin and glucagon concentration, and regulated glucose metabolism \[[@CR12]\]. However, whether or not ingestion of small amounts of Phe combined with or without exercise has similar effects has yet to be determined. Therefore, the purpose of this randomized, double-blind, placebo-controlled, crossover trial was to investigate hormone secretion and substrate catabolism induced by Phe during exercise.

Methods {#Sec2}
=======

Trial design {#Sec3}
------------

This was a randomized, double-blind, placebo-controlled crossover study, conducted at Ritsumeikan University at Shiga, Japan. The study protocol was approved by the Ethics Committee for Human Experiments at Ritsumeikan University and the Meiji Institutional Review Board. All study participants provided written informed consent prior to participation in the study. The study was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. The study protocol was registered in the UMIN Clinical Trials Registry (UMIN000027502) on May 26, 2017 (restrospectively registered).

Subjects {#Sec4}
--------

The inclusion criteria were healthy young men aged 20 to 40 years old. Exclusion criteria consisted of individuals with a history or current condition of severe disease (such as liver disorder, cardiovascular disorder, respiratory disorder, renal disorder, and hypertension), anemia, and those who were judged ineligible by the study physician due to medical examination consultation history or other reasons. Six healthy, active young men were recruited as study volunteers. The baseline characteristics (mean ± deviation (SD)) of the participants were: age, 23.7 ± 1.0 yr.; height, 172.6 ± 7.9 cm; body mass, 67.7 ± 4.9 kg; body mass index (BMI), 22.7 ± 1.1 kg/m^2^; and maximum oxygen uptake, 52.4 ± 4.2 mL/min/kg.

Experimental procedures {#Sec5}
-----------------------

The study involved three visits to the laboratory. At the first visit, maximal oxygen uptake *VO* ~2max~ (mL/kg/min) and maximal heart rate (HR) (beats/min) were measured using an incremental cycle exercise test on a cycle ergometer (828E Monark cycle ergometer). The incremental cycle exercise began at a work rate of 60 W (30--90 W) with power output being increased in 15 W·min^−1^ steps until the subject could not maintain a fixed pedaling frequency of 60 rpm. The subjects were encouraged to exercise at maximum intensity during the ergometer test. Heart rate and rating of perceived exertion (RPE) were monitored every minute during exercise. RPE was obtained using the modified Borg scale. VO~2~ was monitored by breath--by--breath assessment using a respiratory gas analyzer (Aeromonitor AE-310SRD, Minato Medical Science Co., Ltd., Osaka, Japan). The highest 30-s averaged value of VO~2~ during the exercise test was designated as VO~2~peak if three of the following four criteria were met: (1) plateau in VO~2~ with an increase in external work, (2) maximal respiratory exchange ratio ≥ 1.1, (3) HR ≥ 200 beats/min. The results of exhaustion testing were used to calculate the power output equivalent to 50% *VO* ~2max.~ The remaining two visits were separated by at least six days. Dietary intake was self-recorded by the subjects during the study period. The subjects were instructed to refrain from binge eating, strenuous exercise, or drinking alcohol for 24 h prior to each trial and were also instructed to sleep more than eight hours the evening before each visit. At approximately 21:00 on the day before the second and third visits the subjects consumed the same meals that contained 694 kcal (carbohydrate:fat:protein ratio; 57:28:15). The subjects had no food or drink except water between the last meal and the start of each trial. Individual trials were performed at a similar time of the day for each subject (±3 h) to avoid any influence of circadian rhythm on the results.

During the second and third visits the subjects participated in the main experimental trials. Blood samples were drawn from the antecubital vein. The subjects were then randomized to ingest 150 mL of ordinary tap water and either a cellulose capsule containing 3 g of Phe (Kyowa Hakko Bio Co, Ltd., Tokyo, Japan) as the active sample or an empty cellulose capsule (Matsutani Chemical Industry Co., Ltd., Hyogo, Japan) as the placebo (designated as 0 min). The treatments were switched at the crossover phase of the study. After sitting for 30 min (rest period), the subjects mounted a cycle ergometer and commenced cycling for 60 min at a constant power output equivalent to 50% *VO* ~2max~ (exercise period). After exercising, the subjects rested for 60 min in the supine position (post-exercise period). Blood samples were collected at before ingestion of test sample, and 30, 60, 90, and 150 minutes after ingestion. HR was recorded and exhaled air samples were collected throughout the rest, exercise, and post-exercise phases. The tests were conducted in a quiet environment in a controlled room at a temperature of 21 ± 2 °C and humidity of 45 ± 5%. The study design is summarized in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Study design: Study schedule **a** and schedule on experimental trial days (Visit 2 and Visit 3; **b**)

Exhaled gas analysis {#Sec6}
--------------------

Exhaled oxygen and carbon dioxide concentrations were measured by the breath-by-breath method using a same respiration metabolism monitor system de scribed above. Respiratory exchange ratio (RER) was calculated using the expiratory gas measurements 30 s before and after every 10 min period during exercise and every 30 min during recovery.

Blood sampling {#Sec7}
--------------

Whole blood was collected in a vacutainer containing sodium fluoride and ethylenediaminetetraacetic acid (EDTA)-2Na and stored at 4 °C for later analysis of glucose and lactate concentrations. Whole blood from a EDTA-2Na vacutainer with added aprotinin was centrifuged immediately at 1200 g for 10 min at 4 °C, and the plasma separated and frozen immediately at −80 °C for later analysis of glucagon concentration. Whole blood from a EDTA-2Na vacutainer without added aprotinin was centrifuged immediately at 1200 g for 10 min at 4 °C, and the plasma stored at 4 °C for analysis of cortisol concentration. Whole blood from a plain vacutainer was allowed to stand at room temperature for 20 min and then centrifuged at 1200 g for 10 min at 4^o^ C, followed by separation of the serum into two vials. One vial was stored at 4^o^ C for analysis of FFA and growth hormone concentrations, while the other vial was frozen at -80^o^ C for later analysis of acetoacetic acid, 3-hydroxybutyrate, and glycerol concentrations.

Plasma glucagon concentration was measured using the quantitative sandwich enzyme immunoassay (Glucagon Immunoassay R&D systems, Minnesota, USA). Plasma glucose and lactate values were measured using the YSI 2300 STAT Plus Glucose & Lactate Analyzer (YSI Inc., Yellow Springs, Ohio, USA). Serum growth hormone (Access hGH, Beckman Coulter, Inc., USA) and plasma cortisol (Access cortisol, Beckman Coulter, Inc., USA) concentrations were measured by a chemiluminescent enzyme immunoassay. And serum acetoacetic acid, 3-hydroxybutyrate (Total ketone bodies Kainos, 3-HB Kainos, Kainos Co., Ltd., Japan), FFAs (NEFA-HR, Wako Pure Chemical Industries Ltd., Osaka, Japan), and glycerol (Glycerol Colorimetric Assay Kit, Cayman Chemical, Ann Arbor, MI, USA) concentrations were measured by enzymatic methods. The assays to measure acetoacetic acid, 3-hydroxybutyrate, FFAs were performed at Medic Co., Ltd. (Shiga, Japan), and the other assays at the laboratory of Ritsumeikan University.

Statistical analysis {#Sec8}
--------------------

Data were expressed as mean ± SD and analyzed using Microsoft Excel (Microsoft Corp., Redmond, WA, USA). All variables were tested for normal distribution by the F-test using StatView-J 5.0 software (Abacus Conceps, Berkeley, CA, USA). If the data were normally distributed, repeated measures two-factor analysis of variance (ANOVA, time-treatment) was used to examine differences between the biochemical parameters from the two trials. Moreover, when the ANOVA revealed significant effects or interactions between factors, Tukey's post-hoc test was used to detect significant differences between the two treatments. On the other hand, if the data were skewed distribution, Freidman test was used to examine differences. Statistical significance was set at *P* values \<0.05.

Results {#Sec9}
=======

Cardiorespiratory responses {#Sec10}
---------------------------

In RER, there were no outliers, and the data were normally distributed. The changes in RER are shown in Table [1](#Tab1){ref-type="table"}. ANOVA showed a significant treatment × time interaction for RER (treatment *P* = 0.286; time *P* \< 0.01; interaction *P* \< 0.01), with Tukey's post-hoc test showing significant differences between treatments at 40 and 120 min (*P* \< 0.05).Table 1Cardiorespiratory responses of participants0 min40 min50 min60 min70 min80 min90 min120 min150 minPhePlaceboPhePlaceboPhePlaceboPhePlaceboPhePlaceboPhePlaceboPhePlaceboPhePlaceboPhePlaceboRER0.83 ± 0.0300.85 ± 0.0410.90 ± 0.063\*0.97 ± 0.0420.96 ± 0.0200.94 ± 0.0360.95 ± 0.0180.93 ± 0.0450.94 ± 0.0190.93 ± 0.0220.93 ± 0.0260.93 ± 0.0270.93 ± 0.0220.93 ± 0.0160.74 ± 0.057\*0.86 ± 0.0480.80 ± 0.0390.80 ± 0.034F-value1.2100.500.480.200.000.030290.078Values are mean ± SD (*n* = 6)\**p* value for the two factor analysis of variance and Tukey's post-hoc test if data were normally distributed, and Friedman test if not

Biochemical parameters {#Sec11}
----------------------

In blood glycerol, FFA, glucose, and ketone bodies, there were no outliers, and the data were normally distributed. However, in blood lactate, there were outliers, and the data were not normally distributed. The biochemical parameters of the two treatments are summarized in Table [2](#Tab2){ref-type="table"}. ANOVA showed a significant treatment × time interaction for plasma serum glycerol concentration (treatment *P* = 0.022; time *P* \< 0.01; interaction *P* \< 0.01), with Tukey's post-hoc test revealing significant differences between treatments at 90 min (*P* \< 0.05). The blood concentrations of glucose, lactate, FFA, and ketone bodies were not significantly different between the two treatments throughout the experimental period.Table 2Effects of phenylalanine n the blood biochemical parameters0 min30 min60 min90 min150 minTwo factor ANOVA *P* valuePhePlaceboPhePlaceboPhePlaceboPhePlaceboPhePlacebotimetreatmentinteractionGlycerol (mg/L)3.34 ± 1.553.84 ± 1.603.24 ± 1.383.48 ± 1.775.34 ± 0.824.83 ± 1.5115.15 ± 3.02^\*^7.30 ± 1.934.06 ± 1.593.64 ± 1.18*p* \< 0.010.022*p* \< 0.01F-value0.250.0560.27620.18FFAs (mEq/L)0.58 ± 0.160.50 ± 0.210.55 ± 0.170.44 ± 0.150.39 ± 0.110.42 ± 0.200.69 ± 0.280.64 ± 0.330.79 ± 0.300.74 ± 0.17*p* \< 0.010.650.67F-value0.350.820.0590.150.16Total ketone bodies (μmol/L)120 ± 109113 ± 143160 ± 14392.2 ± 97.5114 ± 50.460.3 ± 24.1169 ± 86.0121 ± 107387 ± 401333 ± 412*p* \< 0.010.620.99F-value0.00430.330.210.170.21Glucose (nmol/L)5.08 ± 0.485.18 ± 0.355.21 ± 0.535.09 ± 0.674.89 ± 0.564.87 ± 0.635.35 ± 0.834.89 ± 0.515.15 ± 0.565.04 ± 0.66*p* \< 0.010.690.32F-value0.0750.120.00291.80.10Lactate (nmol/L)1.17 ± 0.221.18 ± 0.181.24 ± 0.181.07 ± 0.313.72 ± 1.813.49 ± 1.053.46 ± 2.592.70 ± 0.831.13 ± 0.141.12 ± 0.15------Values are mean ± SD (n = 6). FFA = free fatty acids\**p* value for the two factor analysis of variance and Tukey's post-hoc test if data were normally distributed, and Friedman test if not

Circulating hormones {#Sec12}
--------------------

In blood glucagon and cortisol, there were no outliers, and the data were normally distributed. However, in blood lactate, there were outliers, and the data were not normally distributed. The concentrations of circulating hormones during each treatment are shown in Table [3](#Tab3){ref-type="table"}. ANOVA showed a significant treatment × time interaction for plasma glucagon (treatment *P* = 0.025; time *P* = 0.035; interaction *P* = 0.039), with Tukey's post-hoc test showing significant differences between treatments at 30, 60, 90, and 150 min (*P* \< 0.05). Growth hormone and cortisol concentrations did not differ significantly between the two treatments throughout the experimental period.Table 3Effects of phenylalanine on the circulating hormones0 min30 min60 min90 min150 minTwo factor ANOVAP valuePhePlaceboPhePlaceboPhePlaceboPhePlaceboPhePlacebotimetreatmentinteractionGlucagon (ng/L)62.9 ± 7.8166.0 ± 19.190.1 ± 29.1^\*^63.6 ± 21.873.5 ± 18.6^\*^52.3 ± 8.7892.2 ± 18.8^\*^61.0 ± 7.7892.3 ± 27.2^\*^61.4 ± 19.70.040.030.04F value0.0785.73.67.87.7Cortisol (μg/L)106 ± 52.2113 ± 32.7109 ± 41.477.6± 23.7146 ± 53.291.9± 34.9173 ± 70.9122 ± 27.5157 ± 51.389.5 ± 31.3*p* \< 0.010.050.11F value0.0721.54.44.07.0Growth hormone (μg/L)1.30 ± 2.010.14 ± 0.081.44 ± 2.800.30 ± 0.469.72 ± 6.8613.1 ± 5.6113.4 ± 14.214.2 ± 8.51.51 ± 0.721.13 ± 1.12------Values are mean ± SD (n = 6)\**p* value for the two factor analysis of variance and Tukey's post-hoc test if data were normally distributed, and Friedman test if not

Discussion {#Sec13}
==========

This study in healthy active young men investigated the acute effects of Phe supplementation combined with exercise on hormone secretion and substrate oxidation. The study showed that, compared with ingestion of a placebo, ingestion of the Phe supplement significantly increased the concentrations of glycerol and glucagon. The RER was also decreased significantly by Phe ingestion. These findings suggest that whole body lipid oxidation increased and that pre-exercise supplementation of Phe stimulated fat oxidation. To the author's knowledge this is the first study to examine the effects of Phe on human fat oxidation combined with exercise. Although considerable evidence exists on the safety of Phe consumption in humans \[[@CR13]\] there is no evidence on the functional effects related to fat oxidation combined with exercise. The data presented in this study lay the groundwork for further investigations on Phe supplementation in sport.

The main mechanism for the stimulation of fat oxidation following Phe administration may be via glucagon secretion. Glucagon is a key hormone involved in fat catabolism during exercise \[[@CR14], [@CR15]\]. Previous reports have noted that several widely divergent effect of glucagon appear to be mediated by a effector, adenosine 3*′*,5*′*-cyclic monophosphate (cAMP) \[[@CR16]\]. The best-known mechanism mediating lipolysis is the cAMP pathway, wherein increased levels of cAMP activate cAMP-dependent protein kinase A (PKA). In this pathway, hormone sensitive lipase (HSL) is phosphorylated by PKA and then translocates from the cytoplasm to the lipid droplet surface, where it interacts with perilipin A, the result of which is a subsequent release of free fatty acids \[[@CR17], [@CR18]\]. HSL is the most important lipase in lipolysis and is subject to hormonal regulation \[[@CR19]\]. In addition to HSL, adipose triglyceride lipase is expressed predominantly in adipose tissue and is considered the rate-limiting lipolytic enzyme in adipocytes \[[@CR20], [@CR21]\]. Therefore, an additional effect by Phe supplementation combined with exercise may stimulate the cAMP-dependent cascade pathway. Previous studies have suggested that glucagon secretion is regulated by gut hormones including glicentin, GLP-1, GIP, and GLP-2 and other peptides secreted by the gastrointestinal tract such as gastrin-releasing peptide (GRP), cholecystokinin (CCK), and secretin \[[@CR22]\]. Further studies are necessary to determine whether or not these hormones are involved in the stimulation of fat oxidation caused by Phe administration.

It has been reported that a single pre-ingestion dose of mixtures of either 17 specific AAs \[[@CR9]\] or 3 AAs \[[@CR10]\] enhanced lipolysis and hepatic ketogenesis during and after exercise by stimulating glucagon secretion. However, in the current study pre-exercise ingestion of Phe increased glycerol concentrations but not ketone body levels. The results suggest that pre-exercise ingestion of Phe markedly stimulate lipolysis but not hepatic ketogenesis. Taken together, these results indicate that ingestion of a specific AA stimulates fat oxidation efficiently during exercise.

In 1970 Harper et al. \[[@CR23]\] published a review of the effects of disproportionate levels of AA intake, with the information subsequently being updated in 1984 by Benevenga and Steeles \[[@CR24]\]. There is concern that Phe supplementation may be associated with abnormal brain development known to occur in humans with phenylketonuria, a condition that results in a buildup of Phe and its metabolites in the blood \[[@CR25]\]. However, no adverse effects were noted in humans given either a single oral dose of up to 10 g \[[@CR26]\], \~30 g i.v. \[[@CR27]\], or 3--4 g orally as aspartame \[[@CR26]\]. No serious or study-related adverse events were observed in the current trial and therefore we conclude that Phe supplementation may be a safe method for accelerating fat oxidation during exercise.

This study has several strengths worth mentioning. First, the trial was a placebo-controlled, double-blind, crossover, randomized, controlled design and therefore the findings are highly reliable. Second, evaluation of the respiratory exchange ratio is regarded as the gold standard for evaluating whole body fat oxidation. Third, the study only administered 3 g of Phe prior to exercise, a low-dose of amino acid supplementation that could be used easily elsewhere.

In contrast, we must also note some limitations. First, the number of enrolled participants was only six of young male. Therefore, the data robustness may not be high. Second, we failed to measure blood insulin levels. Insulin signaling is a key factor for glucagon secretion \[[@CR12]\], so further studies are needed to demonstrate the effect of Phe combined with exercise for insulin secretion. However, stimulation of sympathetic nervous system by exercise suppresses insulin secretion \[[@CR3]\]. Moreover, in our previous report, pre-ingestion of the amino acid mixture containing 1.5 g of Phe did not stimulate insulin secretion during 50% VO~2~max exercise \[[@CR10]\]. Therefore, we thought that the influence of insulin secretion on this fat oxidation effect mediated by Phe ingestion combined with exercise is small. Third, we did not present the data of energy expenditure, so it remains unclear this higher fat oxidation leads to obesity prevention or weight control. However, ingestion of Phe may increase fat mobilization, and this effect might to lead, at least in part, to an increase in fat oxidation during exercise. Further studies are needed to investigate whether this acute response induced by the administration of Phe is sustained if the supplement is ingested over several weeks.

Conclusions {#Sec14}
===========

In conclusion, pre-exercise ingestion of a Phe supplement significantly accelerated secretion of glucagon during both rest and exercise. Furthermore especially serum glycerol levels increased significantly during exercise, indicating a shift towards fat oxidation.
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